Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

Abstract

Background More and more evidence indicates sodium-glucose co-transporter 2 inhibitors (SGLT2is) may display clinical benefits for heart failure with preserved ejection fraction (HFpEF). However, the mechanisms of the action remain unclear. Methods A systematic pharmacology-based strategy was applied for predicting the potential molecular mechanisms of SGLT2is in HFpEF. The potential targets of SGLT2is and HFpEF were contained from diverse databases. After networks were constructed, Metascape was applied to functional enrichment. Moreover, the key findings were validated through molecular docking. Results We obtained 487 SGLT2is related targets and 1505 HFpEF related targets. The networks showed the complex relationship of HFpEF-target-HFpEF. The results of functional enrichment analysis suggested that several biological processes, including muscle system process, inflammatory response, vasculature development, heart development, regulation of MAPK cascade, positive regulation of ion transport, negative regulation of cell population proliferation, cellular response to nitrogen compound, apoptotic signaling pathway, multicellular organismal homeostasis, response to oxidative stress, regulation of cell adhesion, positive regulation of cell death, response to growth factor, and cellular response to lipid, and signaling pathways, such as cardiomyopathy, cAMP signaling pathway, cytokine-cytokine receptor interaction, apoptosis, MAPK signaling pathway, HIF-1 signaling pathway, calcium signaling pathway, and NF-kappa B signaling pathway. Finally, we validated the interactions and combinations of SGLT2is and core targets. Conclusion SGLT2is play the potential role of anti-HFpEF through the direct or indirect synergy of multiple targets and pathways. Our study promotes the explanation of the molecular mechanisms of SGLT2is in HFpEF.

Immune landscape and regulatory mechanisms in human atherosclerotic coronary plaques: Evidence from single-cell and bulk transcriptomics

“…The DEGs from the different cell types clusters and Bulk DEG were independently imported into DAVID 2021 [ 33 ] for Gene Ontology-biological process (BP) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, as described previously [ [34] , [35] , [36] ]. The thresholds were set as count = 2 and EASE score = 0.1.…”

Identification and characterization of four immune-related signatures in keloid

“…At the same time, the STRING database (version 11.0) ( 44 ) was used to construct the protein–protein interaction (PPI) network. Moreover, we used the MCODE plug-in (version 1.32) ( 45 ) in Cytoscape (version 3.8.2) ( 46 ) to identify densely connected networks, as described previously ( 47 , 48 ).…”

Heart Failure in Menopause: Treatment and New Approaches

“…SGLT2i, empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin play the potential role of anti-HFpEF through direct or indirect synergy of multiple targets and pathways. The synergism could occur with targets and signaling pathways involved in inflammation, vasculature development, heart development, regulation of the MAPK cascade, ion transport, cell proliferation, apoptosis, oxidative stress, cell adhesion, upregulation of cell death, growth factor response and cell response to lipids [ 110 ].…”